Mifepristone for management of cushing's syndrome

Pharmacotherapy

Volumn 33, Issue 3, 2013, Pages 319-329

  Morgan, Farah H ^a   Laufgraben, Marc J ^a  

^a Rowan University ^*  (United States)

Author keywords

Cushing's disease; Cushing's syndrome; Glucocorticoid receptor antagonist; Mifepristone; RU486

Indexed keywords

AMINOGLUTETHIMIDE; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLOSPORIN; CYTOCHROME P450; ERGOTAMINE; ETOMIDATE; FENTANYL; FLUINDOSTATIN; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; INSULIN; KETOCONAZOLE; MACROLIDE; METYRAPONE; MEVINOLIN; MIFEPRISTONE; MITOTANE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PASIREOTIDE; PIMOZIDE; PROGESTERONE RECEPTOR; QUINIDINE; RAPAMYCIN; REPAGLINIDE; SIMVASTATIN; TACROLIMUS; WARFARIN;

ACNE; ADRENAL CORTEX INSUFFICIENCY; ALOPECIA; ARTHRALGIA; ARTICLE; ATAXIA; BACKACHE; CONFUSION; CONTROLLED STUDY; CUSHING DISEASE; CUSHING SYNDROME; DECREASED APPETITE; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EDEMA; ENDOMETRIUM HYPERPLASIA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOGONADISM; HYPOKALEMIA; HYPOTENSION; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL IRREGULARITY; MOON FACE; MUSCLE WEAKNESS; MYOPATHY; NAUSEA; NEPHROLITHIASIS; OBESITY; OSTEOPOROSIS; PERIPHERAL EDEMA; PNEUMOCYSTIS PNEUMONIA; QT PROLONGATION; RECOMMENDED DRUG DOSE; REMISSION; SEDATION; SIDE EFFECT; SKIN BRUISING; STRIA; SYMPTOMATOLOGY; VAGINA BLEEDING; VOMITING; WEIGHT GAIN;

CUSHING SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; RECEPTORS, GLUCOCORTICOID;

EID: 84875415776     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1202     Document Type: Article

References (40)

1. Jacobson L. Hypothalamic-pituitary-adrenocortical axis regulation. Endocrinol Metab Clin North Am 2005;34:271-92.
2. Stewart P. The adrenal cortex. In: Kronenberg H, Melmed S, Polonsky KS, Larsen PR, eds. Williams textbook of endocrinology. Philadelphia: Saunders-Elsevier, 2008:445-503.
3. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454-62.
4. Sharma ST, Nieman LK. Cushing's syndrome: all variants, detection and treatment. Endocrinol Metab Clin North Am 2011;40:379-91.
5. Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:1526-40.
6. Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 2011;22:499-506.
7. Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing's syndrome in type 2 diabetes. J Clin Endocrinol Metab 2003;88:5808-13.
8. Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008;93:1553-62.
9. Dorn LD, Lucke JF, Loucks TL, Berga SL. Salivary cortisol reflects serum cortisol: analysis of circadian profiles. Ann Clin Biochem 2007;44:281-4.
10. Bertagna X, Guignat L, Groussin L, Bertherat J. Cushing's disease. Best Pract Res Clin Endocrinol Metab 2009;23:607-23.
11. Atkinson AB, Kennedy A, WIggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long term surveillance. Clin Endocrinol 2005;63:549-59.
12. Imaki T, Tsushima T, Hizuka N, et al. Postoperative plasma cortisol levels predict long-term outcome in patients with Cushing's disease and determine which patients should be treated with pituitary irradiation after surgery. Endocr J 2001;48:53-62.
13. Fleseriu M, Loriaux DL, Ludlam WH. Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful. Curr Opin Endocrinol Diabetes Obes 2007;14:323-8.
14. Prevedello DM, Pouratian N, Sherman J, et al. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg 2008;109:751-9.
15. Castinetti F, Nagai M, Dufour H, et al. Gamma Knife radiosurgery is a successful adjunctive treatment in Cushing's syndrome. Eur J Endocrinol 2007;156:91-8.
16. Liu JK, Fleseriu M, Delashaw JB. Treatment options for Cushing disease after unsuccessful transphenoidal surgery. Neurosurg Focus 2007;23:1-7.
17. Calao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012;366:914-24.
18. Corcept Therapeutics. Korlym (mifepristone) package insert. Menlo Park, CA; 2012.
19. Rizk A, Honegger J, Milian M, Baras T. Treatment options in Cushing's disease. Clin Med Insights Oncol 2012;6:75-84.
20. Dang CN, Trainer P. Pharmacological management of Cushing's syndrome: an update. Arq Bras Endocrinol Metabol 2007;51:1339-48.
21. Sonino N, Boscaro M, Paoletta A, Mantero F, Zilsotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991;35:347-52.
22. Vehelst JA, Trainer PJ, Howlett TA, et al. Short and long term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991;35:169-78.
23. Kamenicky P, Droumaguet C, Salenave S, et al. Mitotain, metyrapone and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011;96: 2796-804.
24. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab 2001;86:4104-8.
25. Casulari L, Naves L, Mello P, Neto AP, Papadiu C. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004;62:300-5.
26. Batista DL, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006;91:4482-8.
27. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary- dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009;94:115-22.
28. Johanssen S, Allolio B. Mifepristone (RU486) in Cushing's syndrome. Eur J Endocrinol 2007;157:561-9.
29. Bertagna X, Escourolle H, Pinquier JL, et al. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab 1994;78:375-80.
30. Laue L, Chrousos GP, Loriaux DL, et al. The antiglucocorticoid and antiprogestin steroid RU486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man. J Clin Endocrinol Metab 1988; 66:290-3.
31. Sartor O, Cutler GB. Mifepristone: treatment of Cushing's syndrome. Clin Obstet Gynecol 1996;39:506-10.
32. Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985;61:536-40.
33. Chrousos GP, Laue L, Nieman L, Vetelsman R, Kawai S, Loriaux DL. Clinical applications of RU486, a prototype glucocorticoid and progestin antagonist. New York, NY: Raven Press, 1989.
34. Chrousos GP, Laue L, Nieman LK, et al. Glucocorticoids and glucocorticoid antagonists: lessons from RU 486. Kidney Int Suppl 1988;26:S18-S23.
35. Garrel DR, Moussali R, De Oliveira A, Lesiege D, Luriviere F. RU486 prevents the acute effects of cortisol on glucose and leucine metabolism. J Clin Endocrinol Metab 1995;80: 379-85.
36. Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009;160:1003-10.
37. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingert DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012;97:1-11.
38. Chu JW, Matthias DF, Belanoff J, Scheitzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high dose mifepristone (RU486). J Clin Endocrinol Metab 2001;86:3568-73.
39. Support Program for Access and Reimbursement of Korlym. 1-855-4Korlym. Verbal communication. May 18, 2012.
40. Support Program for Access and Reimbursement of Korlym. Available from www.korlymspark.com. Accessed May 18, 2012.